PATENT CLAIM ANALYSIS

Application Number: 16009106
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "406000"]

Abstract:
The invention belongs to the field of biomedical research involving the 1,3,4-selenyldiazo derivatives that have cell protective activity. Because there are not so many heterocyclic selenium compounds, we synthesized a new type of selenium analog of BPTES. As the isoacceptor of BPTES, the compounds have antitumor activity, anti-oxidation and cell protection function. Currently many drugs contain the thiodiazo motif, so synthesis of selenyldiazo functional group could further optimize these drugs and are important in new drug development and application.

Claim (Index 9):
The application of the 1,3,4-selenadiazole compounds with pharmaceutical activity of  claim 1 , for cancer treatment, and use in combination with rapamycin, FK506, bacteriocin D, adriamycin, paclitaxel, mitomycin, gemcitabine, 5 fluorouracil, pinocanoic acid, and their derivatives.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.45
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15983079', '14556659', '11830733', '14884997', '16320723']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7572996899753219
- 35 USC 102 Novelty (BERT): 0.5315257972118768
- Combined Prediction Score: 0.7347223006989775
- Mean Citation Score: 267.51160600000003
- Max Citation Score: 308.41116
- Similarity Product: 184.2756578056669

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test